Detailed Narrative
AI-Driven Science and "Lab in the Loop" Workflow
Revvity is experiencing a significant increase in orders directly related to AI, stemming from both traditional pharma/biotech clients and new, non-traditional customers developing AI-driven drug discovery platforms. This trend is fostering a "lab in the loop" workflow, where AI models continuously learn from experimental results, generating unprecedented🌐 data volumes. The company's instruments, reagents, and Signals software are integral to this process, positioning Revvity to capitalize on the evolving preclinical R&D landscape.
Signals Software Business Innovation
Despite a Q2 organic revenue decline of approximately 20% due to challenging year-ago comparisons, the Signals software business is projected to achieve strong double-digit growth in the second half of the year. Recent innovations include the commercial launch of Biodesign for large molecule workflows, the beta rollout of Xynthetica (an AI models as a service platform), and the anticipated release of LabGistics, a workflow coordination layer. Signals AI, which integrates LLM capabilities, and a new connector with Anthropic, further enhance the platform's functionality and customer retention. The "Signals for Start-ups" program aims to broaden market access for emerging biotechs.
Diagnostics Segment Strength
The Diagnostics business delivered exceptional performance in Q2, achieving 11% organic growth, an acceleration from the first quarter. This robust and broad-based growth was driven by strong contributions from Reproductive Health, which grew in the mid-teens, benefiting from continued strength in newborn screening and the Genomics England sequencing contract. Immunodiagnostics outside of China also performed well, accelerating into the high single digits, underscoring the segment's consistency and durability.
Operational Efficiency and Balance Sheet Management
Revvity is making solid progress on the integration of the recently acquired ACD Labs software business and advancing its operational efficiency initiatives, which are expected to yield benefits in H2 2026 and into 2027. The company generated significant cash in Q2, achieving an outstanding 117% conversion of adjusted net income. The repayment of a EUR 500 million note in mid-July is projected to lower gross leverage below 3x and net leverage to approximately 2x by year-end, supported by a strong fixed-rate debt profile.
China Immunodiagnostics Divestiture
A definitive agreement has been executed for the divestiture of Revvity's China immunodiagnostics business, with terms aligning with initial expectations. This transaction is anticipated to conclude by the end of 2027. The strategic decision allows Revvity to concentrate its efforts on end markets where its differentiated capabilities can generate the highest and most sustainable returns. All non-GAAP and organic performance metrics and guidance are presented on a pro forma basis, excluding this divested business.
High-Content Screening Demand
Demand for high-content screening instruments, particularly the new Opera Phenix OptIQ, remains exceptionally strong, exhibiting continued double-digit growth year-over-year. The order velocity for these instruments outpaced near-term production capacity in Q2, resulting in a higher-than-normal instrument backlog as the company enters the second half of the year. This increased customer investment in capacity is expected to drive future demand for related high-content screening reagents.